查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1479066

全球幹細胞檢測市場評估：依檢測類型、依細胞類型、依產品類型、依應用類型、依最終用戶、依地區、機會、預測（2017-2031）

Stem Cell Assays Market Assessment, By Assay Type, By Cell Type, By Product Type, By Application Type, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 223 Pages | 商品交期: 3-5個工作天內

價格

全球幹細胞檢測市場規模預計將從 2023 年的 15.4 億美元增至 2031 年的 48 億美元，在 2024-2031 年的預測期內複合年增長率將達到 15.27%。 近年來市場呈現顯著成長，預計未來將維持穩定擴張速度。 幹細胞測定是評估幹細胞特性和作用的實驗方法。 幹細胞在受控條件下進行測試，以評估其自我更新、分化成不同細胞類型和增殖的能力。 幹細胞檢測在生物醫學研究和再生醫學中非常重要，其應用範圍從藥物發現和開發到毒理學篩檢和疾病建模。 此外，幹細胞檢測透過檢查潛在治療劑對幹細胞分化和功能的影響，在藥物開發中發揮重要作用。 此外，這些測定也用於研究發育過程、篩選藥理學毒性以及研究癌症和神經系統疾病等疾病的根本原因。

幹細胞研究的不斷進步以及幹細胞分離、培養和分化創新技術的出現是主要驅動因素。 這些技術進步提高了幹細胞檢測的效率和有效性，使其對藥物發現、再生醫學和基礎研究等各種應用越來越有吸引力。 3D 細胞培養方法、高通量篩選方法以及成像和分析儀器的進步等創新共同促進了市場的擴張。

幹細胞在治療心血管疾病、神經系統疾病和糖尿病等多種疾病方面的潛力，以及人們對再生醫學的興趣迅速增長，正在推動對幹細胞檢測的需求。 此外，世界各地慢性病和遺傳疾病的增加需要開發新的治療劑和治療方法。 幹細胞代表了產生此類療法的有前途的途徑，推動了疾病建模、藥物開發和個人化醫療中對幹細胞測定的需求。 隨著學術界和製藥公司加強提高我們對疾病發病機制的瞭解並評估新療法，對幹細胞檢測的需求持續增長。 政府、企業和學術機構正在增加對幹細胞研究的投資，以探索治療應用，從而產生對評估幹細胞療法的功效和安全性的檢測的需求。 例如，FUJIFILM Cellular Dynamics 於 2022 年 3 月與 Promega Corporation 合作開發了新的檢測方法，以瞭解細胞生物學在系統中的工作原理，從而最終瞭解人類細胞生物學。

疾病盛行率增加

癌症、心血管疾病、糖尿病和神經系統疾病等慢性病和生活型態相關疾病的盛行率不斷上升，已成為幹細胞檢測市場擴張的關鍵催化劑。 豬流感和伊波拉等傳染病的快速成長也刺激了治療和藥物開發領域的成長。 例如，從2021年12月27日到2022年1月9日，世衛組織全球流感監測和回應系統（GISRS）實驗室分析了來自99個國家實驗室的超過317,198個樣本。 在這些檢測中，16,862人的流感病毒檢測呈陽性，其中63.7%為甲型流感，36.3%為B型流感。 疾病的流行及其復發性證明了幹細胞檢測在瞭解和對抗這些疾病方面的重要性。 此外，隨著老年人和兒童人口的增加，疾病的盛行率也隨之增加，進一步推動了對幹細胞檢測的需求。 截至2022年7月，聯合國預測全球兒童人口（0-17歲）為23億，預計2040年將達25億。 兒科人口的持續成長意味著對創新解決方案的需求不斷增加，幹細胞檢測市場預計在未來幾年將持續成長。

本報告研究和分析了全球幹細胞檢測市場，提供市場規模和預測、市場動態、主要參與者的現狀和前景等。

目錄

第一章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第四章全球幹細胞檢測市場展望（2017-2031）

  • 市場規模與預測
    • 金額
    • 數量
  • 依檢測類型
    • 活力/細胞毒性測定
    • 分離/純化測定
    • 細胞鑑定分析
    • 增殖測定
    • 分化分析
    • 功能測定
    • 細胞凋亡檢測
  • 依細胞類型
    • 成體幹細胞
    • 人類胚胎幹細胞
  • 產品類型
    • 設備
    • 試劑、試劑盒
  • 依使用型
    • 再生醫學/治療方法開發
    • 藥物發現與藥物開發
    • 臨床研究
  • 依最終用戶
    • 生物製藥和生物技術公司
    • 學術機構、研究設施
    • 其他
  • 依地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲最終用戶
    • 中東/非洲
  • 市佔率：依公司劃分（2023 年）

第 5 章全球幹細胞檢測市場展望：依地區劃分（2017-2031 年）

  • 北美
    • 市場規模與預測
    • 依檢測類型
    • 依細胞類型
    • 產品類型
    • 依使用型
    • 依最終用戶
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 南美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 6 章市場地圖（2023 年）

  • 依檢測類型
  • 依細胞類型
  • 產品類型
  • 依使用型
  • 依最終用戶
  • 依地區

第七章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 創新/新技術

第十章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析（2023 年）
  • 併購/合資企業（如果適用）
  • SWOT 分析（5 家市場公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第十三章主要公司展望

  • GE Healthcare Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Merck & Co., Inc.
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Promega Corporation
  • Cell Biolabs, Inc.
  • Danaher Corporation
  • Becton, Dickinson and Company
  • Fujifilm Holdings Corporation

第14章戰略建議

第十五章關於我們公司，免責聲明

Product Code: MX11317

Global stem cell assays market is projected to witness a CAGR of 15.27% during the forecast period 2024-2031, growing from USD 1.54 billion in 2023 to USD 4.8 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. A stem cell assay is a laboratory method used to evaluate the characteristics and actions of stem cells. It involves testing stem cells under controlled conditions to assess their capacity for self-renewal, differentiation into various cell types, and proliferation. Stem cell assays are important in biomedical research and regenerative medicine, offering applications ranging from drug discovery and development to toxicological screening and disease modeling. Moreover, stem cell assays play a crucial role in drug development by examining the effects of potential therapeutic drugs on stem cell differentiation and functionality. Additionally, these assays are employed to study developmental processes, screen for pharmacological toxicities, and investigate the underlying causes of diseases such as cancer and neurological disorders.

Constant progress in stem cell research, coupled with the emergence of innovative techniques for stem cell isolation, cultivation, and differentiation, serve as primary drivers. These technological advancements enhance the efficiency and efficacy of stem cell assays, rendering them increasingly attractive for various applications, including drug development, regenerative medicine, and fundamental research. Innovations such as 3D cell culture methodologies, high-throughput screening approaches, and advancements in imaging and analytical instruments collectively contribute to market expansion.

The burgeoning interest in regenerative medicine, alongside the potential of stem cells to address various ailments such as cardiovascular disease, neurological disorders, and diabetes, fuels the demand for stem cell assays. Moreover, the rising global prevalence of chronic diseases and genetic disorders necessitates the development of novel therapeutics and treatments. Stem cells offer a promising avenue for generating such therapies, consequently driving the demand for stem cell assays in disease modeling, drug development, and personalized medicine. As academia and pharmaceutical companies intensify efforts to deepen their understanding of disease etiology and evaluate new treatments, the necessity for stem cell assays continues to grow. Governments, corporations, and academic institutions are increasingly investing in stem cell research to explore therapeutic applications, thereby generating demand for assays to assess stem cell-based therapies' efficacy and safety. For instance, Fujifilm cellular dynamics collaborated with Promega Corporation in March 2022 to develop novel assays to understand how cellular biology works in a system to understand cell biology in humans ultimately.

Rising Prevalence of Diseases

The increasing prevalence of chronic diseases and lifestyle-related disorders, including cancer, cardiovascular conditions, diabetes, and neurological ailments, serves as a significant catalyst for the expansion of the stem cell assay market. The upsurge in infectious diseases, such as swine flu and Ebola, has also fueled growth in the therapeutics and drug development sector. For instance, between December 27, 2021, and January 9, 2022, WHO Global Influenza Surveillance and Response System (GISRS) laboratories analyzed over 317,198 specimens from labs across 99 countries. Among these tests, 16,862 individuals tested positive for influenza viruses, with 63.7% identified as influenza A and 36.3% as influenza B. The prevalence of diseases and their recurring nature underscore the importance of stem cell assays in understanding and combating these conditions. Moreover, the expanding geriatric and pediatric populations drive the increased incidence of diseases, further boosting the demand for stem cell assays. As of July 2022, United Nations Projections indicated a global pediatric population (0-17 years) of 2.3 billion, projected to reach 2.5 billion by 2040. The ongoing rise in the pediatric population signifies a growing need for innovative solutions, positioning the stem cell assays market for sustained growth in the coming years.

Growing Emphasis On Clinical Research & Development

The expansion of the global stem cell assays market is being propelled by factors such as clinical research and development. There is a strong emphasis on comprehending cancer biology and identifying innovative therapeutic targets for a wide range of acute and chronic diseases, significantly contributing to the growth of the stem cell assays market. Moreover, substantial investments in research and development endeavors by pharmaceutical companies and academic institutions are fostering market expansion. The escalating prevalence of chronic diseases such as cancer, osteoarthritis, cardiovascular diseases, and diabetes drives the demand for cell-based assays in the quest for novel drug discoveries, thereby serving as a pivotal growth factor for this market segment. According to an article titled "2022 Funding forecast: strong R&D growth with clouds on the horizon," published in April 2022, the United States federal government is projected to allocate USD 181.4 billion for research and development in 2022, further bolstering growth prospects for this segment.

Clinical trials play a pivotal role in assessing the safety and efficacy of new drugs, ultimately leading to regulatory approvals and market penetration. These trials validate the therapeutic potential of drugs and augment the empirical evidence supporting their clinical utility. Additionally, collaboration among commercial entities, academic institutions, and regulatory bodies expedites the clinical development process of various stem cell assays and accelerates the introduction of novel drugs to the market. In April 2023, Omisirge (omidubicel-onlv), a significantly modified allogeneic (donor) cord blood-based cell therapy was granted approval by US FDA.

Dominance of Reagent and Kits

During the projected period, the reagents and kits segment are expected to lead the stem cell assays market. These consumables play a vital role in various stem cell tests, encompassing cell proliferation, differentiation, viability, and toxicity assessments. Their pervasive use in routine laboratory operations and recurring necessity contribute to their high demand. This demand is fueled by ongoing research and development endeavors in both academic and commercial sectors, where stem cell assays are pivotal for drug discovery, therapeutic advancement, and fundamental research. Reagents and kits are formulated to address a broad spectrum of requirements, ranging from fundamental research to specialized therapeutic domains. This adaptability is reinforced by the capacity to customize kits for specific stem cell types or assays. Such tailored solutions and application versatility ensure sustained high demand for reagents and kits across diverse research domains and pharmaceutical development initiatives, consolidating their market dominance. Moreover, in contrast to instruments, which entail significant upfront capital investment and maintenance costs, reagents and kits are more cost-effective and accessible to a broader customer base, including small research laboratories and entrepreneurs. In March 2022, Illumina launched the TruSight Oncology (TSO) comprehensive in-vitro genomic profiling kit in Europe. The kit evaluates multiple genes and biomarkers to elucidate the precise molecular profile of cancer patients, empowering clinicians to administer tailored therapies based on individual molecular profiles.

North America Dominates Global Stem Cell Assays Market Share

North America dominates the global stem cell assays market, primarily due to its well-established healthcare sector and widespread adoption of cell-based assays. In the United States, the rising incidence of chronic diseases like cancer, osteoarthritis, and diabetes drives demand for cell-based assays, thus serving as a significant growth driver for this market.

For instance, according to data from the American Cancer Society's Cancer Facts & Figures 2022 report, an estimated 1.9 million new cancer cases will be diagnosed in the United States, along with 609,360 cancer-related deaths. Similarly, American Heart Association reported in January 2022 that a myocardial infarction occurs approximately every 40 seconds in the United States. Such high prevalence of chronic diseases in the population of the United States is expected to propel stem cell assays market growth during the forecast period.

Future Market Scenario (2024 - 2031F)

Occurrence and re-occurrence in number of acute and non-acute diseases call for a solution and it presents the biggest opportunity for the stem cell assays market to rise. Adoption of much advanced and effective approaches are being devised that should ensure faster recovery and better results for a better quality of life. R&D and heavy investments made by healthcare giants are promoting developments in the stem cell assays market, which is optimistic for the market to flourish in the coming years. New brands in this development area are introducing themselves with cutting edge technologies.

For instance, in February 2024, Thermo Fisher unveiled a novel serum-free stem cell culture medium designed to enhance stem cell proliferation and differentiation. The breakthrough holds significant promise for companies engaged in developing stem cell-based therapies. Successful attempts to improve diagnostics push the industry as a whole to engage further with higher-quality R&D, which paves the way for the market to rise. In August 2022, Life Net Health LifeSciences launched Cell-Based Assay Services, including cytotoxicity screening, biocompatibility assays, and others.

Key Players Landscape and Outlook

Several companies in global stem cell assays market are focusing on new product release, market expansion, and product development. Stem cell assays market players are poised to encounter promising growth prospects in the global market, driven by the increasing demand for diagnostic solutions. The primary focus of these leading players is directed towards the rapidly expanding market segment, aiming to thrive and excel in an intensely competitive market environment. Additionally, these market players emphasize collaboration and license agreements as strategic initiatives are anticipated to propel the market growth.

In July 2022, CORESTEM, based in South Korea, continued to enroll participants for the Phase 3 clinical trial of NeuroNata-R. The treatment has obtained conditional approval for the treatment of amyotrophic lateral sclerosis (ALS) patients in South Korea.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Stem Cell Assays Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Assay Type
    • 4.2.1.Viability/Cytotoxicity Assays
    • 4.2.2.Isolation & Purification Assays
    • 4.2.3.Cell Identification Assays
    • 4.2.4.Proliferation Assays
    • 4.2.5.Differentiation Assays
    • 4.2.6.Function Assays
    • 4.2.7.Apoptosis Assays
  • 4.3.By Cell Type
    • 4.3.1.Adult Stem Cells
    • 4.3.2.Human Embryonic Stem Cells
  • 4.4.By Product Type
    • 4.4.1.Instruments
    • 4.4.2.Reagents and Kits
  • 4.5.By Application Type
    • 4.5.1.Regenerative Medicine & Therapy Development
    • 4.5.2.Drug Discovery & Development
    • 4.5.3.Clinical Research
  • 4.6.By End-user
    • 4.6.1.Biopharmaceutical and Biotechnology Companies
    • 4.6.2.Academic Institutes and Research Facilities
    • 4.6.3.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South End-user America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global Stem Cell Assays Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Assay Type
      • 5.1.2.1.Viability/Cytotoxicity Assays
      • 5.1.2.2.Isolation & Purification Assays
      • 5.1.2.3.Cell Identification Assays
      • 5.1.2.4.Proliferation Assays
      • 5.1.2.5.Differentiation Assays
      • 5.1.2.6.Function Assays
      • 5.1.2.7.Apoptosis Assays
    • 5.1.3.By Cell Type
      • 5.1.3.1.Adult Stem Cells
      • 5.1.3.2.Human Embryonic Stem Cells
    • 5.1.4.By Product Type
      • 5.1.4.1.Instruments
      • 5.1.4.2.Reagents and Kits
    • 5.1.5.By Application Type
      • 5.1.5.1.Regenerative Medicine & Therapy Development
      • 5.1.5.2.Drug Discovery & Development
      • 5.1.5.3.Clinical Research
    • 5.1.6.By End-user
      • 5.1.6.1.Biopharmaceutical and Biotechnology Companies
      • 5.1.6.2.Academic Institutes and Research Facilities
      • 5.1.6.3.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
        • 5.1.7.1.1.By Value
        • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Assay Type
        • 5.1.7.2.1.Viability/Cytotoxicity Assays
        • 5.1.7.2.2.Isolation & Purification Assays
        • 5.1.7.2.3.Cell Identification Assays
        • 5.1.7.2.4.Proliferation Assays
        • 5.1.7.2.5.Differentiation Assays
        • 5.1.7.2.6.Function Assays
        • 5.1.7.2.7.Apoptosis Assays
      • 5.1.7.3.By Cell Type
        • 5.1.7.3.1.Adult Stem Cells
        • 5.1.7.3.2.Human Embryonic Stem Cells
      • 5.1.7.4.By Product Type
        • 5.1.7.4.1.Instruments
        • 5.1.7.4.2.Kits and Reagents
      • 5.1.7.5.By Application Type
        • 5.1.7.5.1.Regenerative Medicine & Therapy Development
        • 5.1.7.5.2.Drug Discovery & Development
        • 5.1.7.5.3.Clinical Research
      • 5.1.7.6.By End-user
        • 5.1.7.6.1.Biopharmaceutical and Biotechnology Companies
        • 5.1.7.6.2.Academic Institutes and Research Facilities
        • 5.1.7.6.3.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Assay Type
  • 6.2.By Cell Type
  • 6.3.By Product Type
  • 6.4.By Application Type
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.GE Healthcare Technologies Inc.
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Thermo Fisher Scientific Inc.
  • 13.3.Merck & Co., Inc.
  • 13.4.Bio-Rad Laboratories, Inc.
  • 13.5.Bio-Techne Corporation
  • 13.6.Promega Corporation
  • 13.7.Cell Biolabs, Inc.
  • 13.8.Danaher Corporation
  • 13.9.Becton, Dickinson and Company
  • 13.10.Fujifilm Holdings Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 2.Global Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 4.Global Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 5.Global Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 6.Global Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 7.Global Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global Stem Cell Assays Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 10.North America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 12.North America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 13.North America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 14.North America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 15.North America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 18.United States Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 20.United States Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 21.United States Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 22.United States Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 23.United States Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 25.Canada Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 27.Canada Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 28.Canada Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 29.Canada Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 30.Canada Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 32.Mexico Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 34.Mexico Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 35.Mexico Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 36.Mexico Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 37.Mexico Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 39.Europe Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 41.Europe Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 42.Europe Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 43.Europe Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 44.Europe Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 45.Europe Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 46.Germany Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 47.Germany Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 49.Germany Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 50.Germany Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 51.Germany Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 52.Germany Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 53.France Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 54.France Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 56.France Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 57.France Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 58.France Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 59.France Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 61.Italy Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 63.Italy Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 64.Italy Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 65.Italy Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 66.Italy Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 68.United Kingdom Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 70.United Kingdom Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 71.United Kingdom Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 72.United Kingdom Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 73.United Kingdom Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 75.Russia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 77.Russia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 78.Russia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 79.Russia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 80.Russia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 82.Netherlands Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 84.Netherlands Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 85.Netherlands Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 86.Netherlands Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 87.Netherlands Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 89.Spain Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 91.Spain Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 92.Spain Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 93.Spain Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 94.Spain Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 96.Turkey Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 98.Turkey Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 99.Turkey Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 100.Turkey Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 101.Turkey Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 103.Poland Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 105.Poland Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 106.Poland Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 107.Poland Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 108.Poland Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 110.South America Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 112.South America Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 113.South America Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 114.South America Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 115.South America Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 118.Brazil Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 120.Brazil Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 121.Brazil Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 122.Brazil Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 123.Brazil Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 125.Argentina Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 127.Argentina Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 128.Argentina Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 129.Argentina Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 130.Argentina Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 132.Asia-Pacific Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 134.Asia-Pacific Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 135.Asia-Pacific Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 136.Asia-Pacific Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 137.Asia- Pacific Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 139.India Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 140.India Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 142.India Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 143.India Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 144.India Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 145.India Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 146.China Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 147.China Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 149.China Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 150.China Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 151.China Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 152.China Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 154.Japan Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 156.Japan Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 157.Japan Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 158.Japan Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 159.Japan Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 161.Australia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 163.Australia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 164.Australia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 165.Australia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 166.Australia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 168.Vietnam Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 170.Vietnam Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 171.Vietnam Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 172.Vietnam Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 173.Vietnam Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 175.South Korea Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 177.South Korea Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 178.South Korea Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 179.South Korea Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 180.South Korea Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 182.Indonesia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 184.Indonesia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 185.Indonesia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 186.Indonesia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 187.Indonesia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 189.Philippines Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 191.Philippines Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 192.Philippines Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 193.Philippines Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 194.Philippines Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 196.Middle East & Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 198.Middle East & Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 199.Middle East & Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 200.Middle East & Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 201.Middle East & Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa Stem Cell Assays Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 204.Saudi Arabia Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 206.Saudi Arabia Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 207.Saudi Arabia Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 208.Saudi Arabia Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 209.Saudi Arabia Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 211.UAE Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 213.UAE Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 214.UAE Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 215.UAE Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 216.UAE Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa Stem Cell Assays Market, By Value, In USD Billion, 2017-2031F
  • Figure 218.South Africa Stem Cell Assays Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa Stem Cell Assays Market Share (%), By Assay Type, 2017-2031F
  • Figure 220.South Africa Stem Cell Assays Market Share (%), By Cell Type, 2017-2031F
  • Figure 221.South Africa Stem Cell Assays Market Share (%), By Product Type, 2017-2031F
  • Figure 222.South Africa Stem Cell Assays Market Share (%), By Application Type, 2017-2031F
  • Figure 223.South Africa Stem Cell Assays Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Assay Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225.By Cell Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227.By Application Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023